ifrx stock: InflaRx (IFRX) Guide

InflaRx (IFRX)

Quick lead: ifrx stock refers to InflaRx N.V. (ticker: IFRX), a Nasdaq‑listed, clinical‑stage biopharmaceutical company headquartered in Jena, Germany, focused on inhibitors of the complement activation factor C5a/C5aR. IFRX trades on the Nasdaq in the Healthcare — Biotechnology sector and is typically classified as a micro‑cap stock. This article explains the company, its development pipeline, trading profile, financial position, regulatory risks, and how investors commonly access ifrx stock — with data references noted as of 2026-01-29.

Company overview

ifrx stock represents InflaRx N.V., a clinical‑stage biopharmaceutical company founded to develop therapies that modulate innate immunity by targeting the complement pathway, specifically the C5a/C5aR axis. Headquartered in Jena, Germany, InflaRx focuses on monoclonal antibodies and small molecules intended to treat severe inflammatory and complement‑mediated diseases. The company's business model centers on advancing lead candidates through clinical trials, pursuing regulatory approvals, and, where appropriate, partnering or licensing programs for commercialization and late‑stage development.

History and corporate milestones

• Founding and early R&D: InflaRx was established to pursue complement inhibition strategies with a focus on C5a antagonism. Early preclinical work validated C5a as a target in multiple inflammatory indications.
• Clinical development milestones: The company progressed candidate vilobelimab (also known by program names such as IFX‑1/GOHIBIC in some trials) into multiple clinical trials across indications including hidradenitis suppurativa, pyoderma gangrenosum, various dermatologic and systemic inflammatory conditions, and investigations in acute settings. Small‑molecule programs (e.g., izicopan/INF904) were developed to inhibit complement components by oral administration.
• Public listing and ticker: InflaRx completed a U.S. public listing and trades under the ticker IFRX on the Nasdaq. The listing was intended to improve access to U.S. capital markets and broaden the investor base supporting clinical development.
• Notable corporate events: Across its history InflaRx announced strategic refocuses, trial initiations and readouts, and workforce adjustments aligned with program priorities. The company periodically raised capital via equity financing and collaborations to fund ongoing trials.

As of 2026-01-29, per InflaRx corporate disclosures and market data providers, these milestones remain central to investor assessment of ifrx stock.

Products and research pipeline

InflaRx's pipeline historically centers on two program types:

• Vilobelimab (anti‑C5a monoclonal antibody): The company's lead biologic has been evaluated in multiple clinical trials across inflammatory and dermatological indications. Trial designs ranged from Phase 1 safety studies to Phase 2/3 efficacy trials. Reported results from some trials provided proof‑of‑mechanism signals in targeted patient populations, while other indications required further study or reprioritization based on outcomes and safety findings.

• Small‑molecule complement inhibitors (e.g., izicopan / INF904): These oral candidates aim to provide complement pathway inhibition via small molecules with potential advantages in administration and chronic treatment settings. Clinical stages for small‑molecule programs have included early‑phase dose‑finding and safety assessments.

As of 2026-01-29, per company press releases and clinical trial registries, vilobelimab remained the most advanced program in InflaRx’s portfolio, with ongoing or planned trials in select indications. Investors evaluating ifrx stock should consult primary sources (company announcements and trial registries) for the latest status, since trial progress and readouts materially affect valuation.

Stock information

• Ticker symbol: IFRX (commonly referenced as ifrx stock).
• Primary exchange: Nasdaq (U.S. market listing).
• Sector / industry: Healthcare — Biotechnology.
• Typical classification: Micro‑cap (subject to change with share price and outstanding shares).
• Float and liquidity indicators: ifrx stock historically shows lower float and variable average daily volume relative to larger biotech peers; low float can amplify price swings around news events.

As of 2026-01-29, market‑data services (Nasdaq, Morningstar, Finviz) categorize IFRX as a small/micro‑cap biotechnology equity; precise market cap and float should be checked on official market pages and recent filings for accuracy before making decisions.

Trading data and price performance

Market behavior for ifrx stock typically reflects these patterns:

• Price sensitivity to clinical news: trial readouts, regulatory updates, and partnership announcements can drive significant intraday and multi‑day moves.
• 52‑week highs/lows and volatility: IFRX’s 52‑week range and implied volatility fluctuate with program developments and liquidity; biotech micro‑caps often show higher realized volatility compared with large‑cap stocks.
• Average volume: trading volumes can vary widely; spikes usually align with press releases or sector news. Retail sentiment channels and micro‑cap traders sometimes concentrate activity, leading to episodic volume surges.

As of 2026-01-29, investors should consult Nasdaq and market‑data pages for IFRX’s latest close price, 52‑week high/low, and average daily volume figures. Historical performance trends for ifrx stock commonly show multi‑month periods of low activity punctuated by high‑impact events.

Market data & metrics

Commonly reported metrics for biotech companies like InflaRx include:

• Price/Earnings (P/E): Not meaningful for many clinical‑stage biotech firms that report net losses; P/E may be negative or unavailable for ifrx stock.
• Price/Book and Price/Sales: These ratios can be used for cross‑company comparison, but may be of limited interpretive value for early‑stage biotechs with minimal revenues.
• EPS (TTM): Expected to be negative for a clinical‑stage company; EPS trends reflect R&D spending and financing activities.
• Debt/Equity and cash per share: Balance‑sheet metrics are crucial — cash reserves and burn rate drive financing needs and dilution risk.

As of 2026-01-29, financial databases such as Morningstar and Finviz provide snapshot metrics for IFRX. Because these metrics change with quarterly filings and share issuance, always cross‑check with the latest 10‑Q/20‑F or company announcements.

Short interest and ownership

• Insider ownership: Founders, management and board members often hold equity; insider filings indicate recent trades and ownership levels.
• Institutional ownership: Coverage by institutional investors can be limited for micro‑cap biotechs; institutional ownership percentages are tracked by market‑data providers.
• Short interest: Short positions in ifrx stock are monitored because high short interest in a low‑float name can increase volatility and the potential for rapid squeezes if positive news occurs.

As of 2026-01-29, market trackers such as Nasdaq and specialized data vendors report short interest and institutional holdings for IFRX; investors should review those figures to understand potential liquidity and volatility dynamics.

Financials

Clinical‑stage biotechs like InflaRx frequently exhibit the following financial profile:

• Revenue: Limited or no product revenue if no commercial product is approved; operating activity is financing and R&D intensive.
• Net loss: Ongoing R&D and clinical trial spending typically produce net losses reported each quarter.
• Cash and runway: Cash on hand and the projected runway (months of operating coverage) are critical. Companies often raise capital by equity offerings, convertible notes, or strategic partnerships to fund trials and operations.

As of 2026-01-29, InflaRx’s most recent quarterly and annual reports (refer to SEC filings or company investor releases) provide the latest figures for cash balance, quarterly burn rate, revenues (if any), and guidance on financing plans. Because cash runway directly affects dilution risk for holders of ifrx stock, these filings are primary source documents for investors.

Analyst coverage and investor sentiment

• Analyst ratings and price targets: Coverage of ifrx stock by sell‑side analysts may be limited compared with larger biotech names. Where coverage exists, analysts typically emphasize clinical milestones and financing outlook in forming price targets.
• Retail sentiment: Channels such as investor forums and social platforms (e.g., StockTwits) frequently discuss ifrx stock; retail sentiment can amplify short‑term price moves, particularly in low‑liquidity names.

As of 2026-01-29, public commentary and analyst notes (from providers like Morningstar, SoFi, and financial news outlets) influence trading flows in IFRX. Investors should treat retail sentiment as a market force but rely on primary filings and peer‑reviewed clinical data for substantive investment research.

Regulatory and legal matters

• Regulatory interactions: Trials for vilobelimab and other programs require regulatory clearances (e.g., protocol approvals, IND amendments, or interactions with the FDA/EMA). Positive regulatory feedback can de‑risk development; negative findings or clinical holds can materially affect ifrx stock.
• Legal/compliance issues: Any material litigation, enforcement action, or compliance issue would be disclosed in company filings and can have significant implications for valuation and operations.

As of 2026-01-29, InflaRx’s public filings and press releases are the authoritative sources for regulatory status and legal disclosures relevant to ifrx stock.

Risk factors

Principal risks that commonly apply to ifrx stock include:

• Clinical trial failure: Efficacy or safety failures in key trials can greatly reduce the value of pipeline‑centric companies.
• Regulatory risk: Approval pathways are uncertain; regulators may request additional data or deny applications.
• Cash burn and dilution: Limited revenue sources mean continued reliance on financing; equity raises dilute existing shareholders.
• Market and sector volatility: Biotechnology stocks, especially micro‑caps, are sensitive to macro market moves and sector rotations.
• Liquidity and concentration: Low float and concentrated ownership may produce outsized price moves on relatively small trade volumes.

These risks are material to investors considering exposure to ifrx stock and are detailed in company filings and investor‑facing risk disclosures.

Recent developments (news)

• As of 2026-01-29, per InflaRx press releases and market coverage, the company reported ongoing development activities for its lead programs. Investors should consult the company’s press release archive and SEC filings to confirm recent trial starts, interim analyses, or financing announcements affecting ifrx stock.
• Market news outlets and data providers (Business Insider / Markets, CNN Markets, Morningstar) periodically publish coverage and quotes that capture market reactions to InflaRx announcements. Retail platforms (Robinhood, Public, SoFi) provide access to quotes and user sentiment indicators for IFRX.

When reviewing recent news for ifrx stock, prioritize dated press releases and filings to ensure the chronology and materiality of events are clear.

Corporate governance and management

InflaRx’s management team and board composition are important for strategic execution. Key governance considerations include leadership experience in biotech development, recent executive changes, and committee structures overseeing audit and compliance. Insider transactions and governance disclosures are filed in the company’s investor relations materials and regulatory filings — essential references for assessing stewardship over programs that drive ifrx stock performance.

Investor relations and filings

Official investor materials for InflaRx include:

• SEC filings (for U.S.‑listed entities) such as 20‑F, 6‑K, 10‑Q equivalents and proxy statements.
• Investor presentations, earnings releases and shareholder letters published on the company’s investor relations site.
• Clinical‑trial registry entries providing protocol details and enrollment status.

As of 2026-01-29, prospective readers and holders of ifrx stock should rely on these primary sources for materially accurate information; market‑data pages supplement but do not replace official filings.

How to trade IFRX

Practical notes for accessing ifrx stock:

• Trading venues and brokers: IFRX is listed on the Nasdaq, and U.S. broker‑dealers and retail brokerage platforms commonly provide quote and execution access for ifrx stock. For users of Bitget, IFRX may be available through stock‑listing features or tokenized stock products if supported by Bitget’s services — check Bitget’s platform product list and official announcements for availability. When trading on Bitget, use market and limit orders, consider order size relative to average volume, and be mindful of potential slippage in low‑liquidity names.

• Order types and execution considerations: Limit orders can help control execution price in volatile, low‑liquidity stocks like IFRX. Market orders may execute at unfavorable prices during wide bid‑ask spreads. For significant position sizes, consider working orders or algorithmic execution where available.

• Risk reminders: Trading ifrx stock carries clinical and financing risks, and retail investors should consult up‑to‑date market data and primary filings. This article does not provide investment advice.

• Wallets and custody for tokenized products: If trading tokenized forms of equities (where offered by a platform), custody and wallet arrangements vary. Bitget Wallet is recommended for Web3 custody related to Bitget ecosystem products; verify custody and regulatory terms for any tokenized stock offering.

See also

• Biotechnology industry overview
• Clinical‑stage biotech investing
• Complement system biology: C5a and C5aR

References

Note: Accurate, current data for ifrx stock is best obtained from primary filings and market‑data sites. Representative sources commonly used for IFRX coverage include: InflaRx corporate press releases and investor relations materials; Nasdaq quote and company pages; Markets/Business Insider market coverage; broker platforms (Robinhood, SoFi, Public) for retail metrics and sentiment; Finviz and Morningstar for financial snapshots; CNN Markets for headline summaries; StockTwits for retail discussion. Specific data points cited in this article reference company filings and market pages as of 2026-01-29.

• As of 2026-01-29, per InflaRx investor materials and Nasdaq listings, IFRX remains listed on Nasdaq.
• As of 2026-01-29, per Morningstar and Finviz snapshots, IFRX is classified in the Healthcare — Biotechnology sector.
• As of 2026-01-29, retail‑platform summaries (Robinhood, Public, SoFi) and social channels (StockTwits) reflect ongoing public interest in ifrx stock.

(Readers should consult the primary sources above for exact figures and recent filings.)

External links

Official sources to consult (search these names on the web or via your brokerage): InflaRx corporate site and investor relations pages; Nasdaq quote page for IFRX; major market‑data providers such as Morningstar, Finviz, Business Insider / Markets, and broker pages (Robinhood, SoFi, Public) for up‑to‑date trading data.

Further exploration: To follow ifrx stock closely, subscribe to InflaRx investor alerts, monitor Nasdaq quotes, and use Bitget’s market tools for execution and custody options. Always verify the latest filings before making trading decisions and consider consulting a licensed financial professional for personal investment guidance.

Explore IFRX trading features on Bitget and secure custody with Bitget Wallet to stay ready for news‑driven moves — check platform availability and disclaimers within Bitget’s official product pages.